Cargando…

24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients

OBJECTIVE: The objective of this study was to evaluate the safety and intraocular pressure (IOP)-lowering effects over 24 months of biodegradable bimatoprost sustained-release implant (Bimatoprost SR) administration versus topical bimatoprost 0.03% in patients with open-angle glaucoma (OAG). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Craven, E. Randy, Walters, Thomas, Christie, William C., Day, Douglas G., Lewis, Richard A., Goodkin, Margot L., Chen, Michelle, Wangsadipura, Veronica, Robinson, Michael R., Bejanian, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007425/ https://www.ncbi.nlm.nih.gov/pubmed/31884564 http://dx.doi.org/10.1007/s40265-019-01248-0

Ejemplares similares

Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
por: Seal, Jennifer R., et al.
Publicado: (2019)

Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)
por: Bacharach, Jason, et al.
Publicado: (2021)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Dose–Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure
por: Lee, Susan S., et al.
Publicado: (2019)

Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
por: Weinreb, Robert N., et al.
Publicado: (2023)

Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty
por: Ghosn, Corine, et al.
Publicado: (2022)

Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol in Glaucoma and Ocular Hypertension in India: A Multicenter, Open-Label, Phase 3 Study
por: Menon, Meena G, et al.
Publicado: (2022)

Bimatoprost in Dermatology
por: Jha, Abhijeet K., et al.
Publicado: (2018)

Hirsutism following the use of bimatoprost eyedrops for glaucoma
por: Kaliaperumal, Subashini, et al.
Publicado: (2014)

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
por: Xu, Kai Man, et al.
Publicado: (2022)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Medeiros, Felipe A., et al.
Publicado: (2022)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen, Jie, et al.
Publicado: (2017)

Intraocular Pressure Effects and Mechanism of Action of Topical Versus Sustained-Release Bimatoprost
por: Lee, Susan S., et al.
Publicado: (2019)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Bimatoprost in the treatment of eyelash hypotrichosis
por: Law, Simon K
Publicado: (2010)

Bimatoprost Implant: First Approval
por: Shirley, Matt
Publicado: (2020)

Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 µg and Selective Laser Trabeculectomy in Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Christie, William C, et al.
Publicado: (2023)

Bimatoprost-Loaded Ocular Inserts as Sustained Release Drug Delivery Systems for Glaucoma Treatment: In Vitro and In Vivo Evaluation
por: Franca, Juçara Ribeiro, et al.
Publicado: (2014)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin, Joan-En, et al.
Publicado: (2011)

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon
por: Shen, Jie, et al.
Publicado: (2016)

Management of hypotrichosis of the eyelashes: Focus on bimatoprost
por: Fagien, Steven
Publicado: (2010)

Correction to: Bimatoprost Implant: First Approval
por: Shirley, Matt
Publicado: (2020)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% — an observational switch study
por: Deshpande, Sarita S, et al.
Publicado: (2017)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
por: Inoue, Kenji, et al.
Publicado: (2012)

Ocular Delivery of Bimatoprost-Loaded Solid Lipid Nanoparticles for Effective Management of Glaucoma
por: Satyanarayana, Sandeep Divate, et al.
Publicado: (2023)

Nonclinical Pharmacokinetic and Pharmacodynamic Assessment of Bimatoprost Following a Single Intracameral Injection of Sustained-Release Implants
por: Shen, Jie, et al.
Publicado: (2020)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
por: Filippelli, Mariaelena, et al.
Publicado: (2022)

Bimatoprost Effects on Aqueous Humor Dynamics in Monkeys
por: Woodward, David F., et al.
Publicado: (2010)

An Effect of Bimatoprost: Adverse for Some, Therapeutic for Others
por: Dubey, Ashok Kumar
Publicado: (2011)

Bimatoprost in the Treatment of Eyelash Universalis Alopecia Areata
por: Vila, Teresa Ojeda, et al.
Publicado: (2010)

The biodisposition and hypertrichotic effects of bimatoprost in mouse skin
por: Woodward, David F, et al.
Publicado: (2013)

Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis
por: Chanasumon, Nongsak, et al.
Publicado: (2018)

Tear biomarkers in latanoprost and bimatoprost treated eyes
por: Reddy, Shweta, et al.
Publicado: (2018)

Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis
por: Carruthers, Jean, et al.
Publicado: (2016)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_45ba3t0tr2cj9jpspu8vtr8l45